Sana Ozair
Hematology & Oncology · Mobile, ALNPI 1710448931
Payments from drug & device makers
Across 170 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$655
- Novartis$530
- E.r. Squibb & Sons, L.L.C.$449
- Seagen Inc.$402
- Lilly USA, LLC$267
- Pfizer$166
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,27385%
- Education$55615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $655 |
| Novartis | 28 | $530 |
| E.r. Squibb & Sons, L.L.C. | 21 | $449 |
| Seagen Inc. | 6 | $402 |
| Lilly USA, LLC | 10 | $267 |
| Pfizer | 14 | $166 |
| Eisai Inc. | 8 | $139 |
| Incyte Corporation | 7 | $134 |
| Bristol Myers Squibb | 4 | $110 |
| Beigene USA, Inc. | 5 | $97 |
| Merck | 5 | $97 |
| Johnson & Johnson | 5 | $91 |
| GSK | 4 | $80 |
| Tersera Therapeutics LLC | 3 | $67 |
| Taiho Oncology, Inc. | 3 | $46 |
| Blueprint Medicines Corporation | 2 | $44 |
| Sobi, Inc | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| EMD Serono, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| CTI Biopharma Corp. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| Genmab U.S., Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,830 in reported general payments places this provider in the 25th percentile of 177 hematology & oncology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 14 | $216,769 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $267 | $216,76914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Mobile
- Michael MeshadMobile$5.3M
- Jose Galeas SorianoMobile$536K
- Anita MazloomMobile$454K
- Sherri ArledgeMobile$358K
- Brian HellerMobile$213K
- Thaddeus BeekerMobile$195K
- Prajwol PathakMobile$158K
- Ahmed AbdallaMobile$141K
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.